Wegovy 7.2mg Availability: What UK Patients Need to Decide

What the April 2026 approval actually changed

Before 14 April 2026, reaching 7.2mg required three separate 2.4mg injections in a single week, a format that worked clinically but was cumbersome in practice. The new dedicated pen delivers the full 7.2mg in one weekly injection, using an auto-dosing mechanism with a built-in covered needle that locks after use. The MHRA's approval of this pen makes the dose far more practical for patients already established on semaglutide and looking to push further. For context on the full approved range, the complete list of Wegovy doses available in the UK covers how this fits alongside the existing 0.25mg to 2.4mg steps.

It is worth being clear about what the approval does not change: 7.2mg remains the ceiling, not a new starting point. Titration still begins at 0.25mg. The prescriber's job is to move you through each level at a pace your system tolerates, and only to continue if you are responding. That process takes months, not weeks, something to factor in if you are planning around a specific date, whether that is a summer holiday or a new year's resolution. If you are trying to work out a realistic timeline for reaching the higher dose, our page on when the Wegovy 7.2mg pen will be available sets out what to expect at each stage.

The clinical detail behind the 7.2mg dose goes deeper into the mechanism and the evidence base if you want the full picture before your consultation.

Who the 7.2mg pen is actually licensed for

The MHRA's approval is specific: the 7.2mg pen is licensed for adults with a BMI of 30 or above, alongside a reduced-calorie diet and increased physical activity. It is not licensed for people using Wegovy solely under the lower 27–29.9 BMI threshold, even if they have a weight-related condition. It is also separate from the cardiovascular indication, which runs under its own evidence base and eligibility criteria.

In practice, reaching 7.2mg means you would already have been on semaglutide at 2.4mg and tolerated it well. Patients transferring from another provider at the 2.4mg level can move toward 7.2mg, but a prescriber will want evidence of current treatment before adjusting anything. Lower BMI thresholds of 2.5 kg/m² can apply for South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds under UK clinical guidance, your prescriber applies these individually.

If you are still working out where semaglutide sits alongside other options, our Wegovy overview covers the full licensed picture. For a broader comparison of the injectable options currently available, the weight-loss treatments page sets out the landscape without steering you toward one medicine prematurely.

The 7.2mg trial evidence, and what it means for your expectations

The headline figure from trials at 7.2mg is around 20.7% average weight loss over 72 weeks. That brings semaglutide materially closer to the results seen in the SURMOUNT-1 trial of tirzepatide at 15mg, which reported around 20–21% average reduction, a comparison that the Wegovy price comparison page also touches on in cost terms. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average loss than semaglutide 2.4mg; the 7.2mg data suggests that gap narrows at the higher semaglutide dose, though no direct head-to-head at 7.2mg versus tirzepatide has been published. These are population averages from controlled trials, not personal forecasts.

The side-effect profile at 7.2mg is consistent with the rest of the semaglutide range (gastrointestinal effects remain the most commonly reported) but the picture at the higher dose is still being gathered through the MHRA's ongoing post-approval monitoring. The MHRA's Yellow Card scheme is the route for reporting any suspected side effect, and patients on the 7.2mg pen are encouraged to use it. For a thorough summary of the semaglutide evidence base, the NHS semaglutide medicines page is the clearest starting point.

Getting access through a private route

Wegovy 7.2mg is not available on the NHS at launch, a NICE appraisal would need to follow before NHS commissioning. Private prescribing is the current route, through a GPhC-registered online pharmacy after a clinical assessment. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber (a named clinician, not automated software) and once approved, treatment dispatches the same day for free next-working-day tracked delivery via DPD.

One practical note: if you order around a bank holiday or at the turn of the month, the same-day cut-off still applies on working days. Planning your repeat order for a weekday rather than a Friday means your pen arrives before the weekend rather than Monday.

Specific dose availability is confirmed at consultation, since stock and clinical suitability both factor in. For broader questions about what the consultation covers, our FAQs are a good reference. When you are ready, check your eligibility and our prescribers will take it from there.